ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) announced that the company has changed its name toIonis Pharmaceuticals, Inc.
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) announced the initiation of an investigator-sponsored, open-label Phase 2 study evaluating ISIS-TTRRx in patients with wild-type transthyretin amyloidosis (wt-TTR amyloidosis, …
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) announced that its partner, Biogen, has initiated a Phase 1/2 clinical study of ISIS-SOD1Rx (BIIB067) in patients with amyotrophic …
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) announced the initiation of a Phase 2 study evaluating ISIS-FXIRx in patients with end-stage renal disease (ESRD) on hemodialysis.
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) announced that its collaboration with AstraZeneca to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases has …
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) reported net income of $35.
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), announced that the FOCUS FH phase 3 study of KYNAMRO® (mipomersen sodium) in patients with severe heterozygous familial hypercholesterolemia (severe …
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) and AstraZeneca plc (ADR) (NYSE:AZN) announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and …
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) announced encouraging preliminary results from an investigator-sponsored study in patients with transthyretin amyloid-related cardiomyopathy that was presented yesterday by …
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in RNA-targeted therapeutics, and Akcea Therapeutics announced today that The Lancet has published clinical data evaluating ISIS-APO(a)Rx in healthy volunteers …
